Bio-Techne stock
Price history
+24.17% over the period1 year: from $58.61 (November 17, 2025) to $72.78 (November 17, 2026), +24.17%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | $72.78 |
| October 30, 2026 | $72.66 |
| September 30, 2026 | $72.47 |
| August 31, 2026 | $72.31 |
| July 31, 2026 | $72.09 |
| June 30, 2026 | $70.65 |
| May 29, 2026 | $51.68 |
| April 30, 2026 | $55.32 |
| March 31, 2026 | $52.26 |
| February 27, 2026 | $59.00 |
| January 30, 2026 | $64.09 |
| December 31, 2025 | $58.81 |
| November 28, 2025 | $64.51 |
| November 17, 2025 | $58.61 |
At a glance
The company
Develops and manufactures life science reagents, instruments and services for research, diagnostics and bioprocessing markets globally
Latest results
Quarter to September 30, 2026 · EPS $0.44 (estimate $0.45)
TickerLandia's take on Bio-Techne
- Priced as usual relative to earnings: P/E on the latest fiscal year 63 vs a median of 65 over its last 6 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 67 vs 67 (−0%) in a group of 7.
- Strong point: Earnings stability (83/100 in its group). Weak point: Growth (25/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−0.34% from the 52-week high
Analysts · 13 analysts
Average target$70.50−2.93% vs. price
Buy 0 · Hold 12 · Sell 1 · Hold
TickerLandia Fingerprint: Bio-Techne
Compared with similar companies: very high earnings stability.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.
Priceaverage60
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 31.5 59 EV/EBITDA 34.9 70 Price/sales 9.31 48 P/E (trailing 12 months) 66.8 76 Price/book 5.28 47 Profitabilityaverage50
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 66.2% 39 Operating margin 21.7% 57 Net margin 14.0% 55 ROE 8.3% 43 ROA 6.5% 57 Earnings stabilityvery high83
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 7.5% 82 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 84 Growthlow25
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +2.25% 11 Revenue growth (year over year) +4.60% 23 Earnings growth (year over year) −25.00% 40 Financial strengthaverage43
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 0.07 33 Interest coverage 28.5 66 Debt/equitycounts in reverse: lower means more financial strength 0.13 49 Current ratio 2.28 25 Dividendaverage49
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 19 years 76 Payout ratio 36.7% 53 Dividend yield 0.4% 19 Market momentumstrong76
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +3.52% 59 Relative strength (6 months) +64.70% 98 1-year return +22.58% 65 Distance from 200-day average +14.77% 82 Risklow40
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 39.3% 72 Volatility (60 days) 1.8% 0 Beta (1 year) 0.61 47
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 17, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Bio-Techne is priced as in the past and in line with similar companies
On the latest fiscal year's earnings (2026), Bio-Techne's P/E today is 62.7, in line with the median of its last 6 fiscal years (64.6; between 46.4 and 129.4 from 2021 to 2026). Bio-Techne's P/E (trailing 12 months): 66.8, in line with the median of a group of 7 similar companies (66.8).
Compared with 7 similar companies
| Metric | Bio-Techne | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 66.8 | Middle | |
| Forward P/E | 31.5 | High | |
| Operating margin | 21.7% | Middle | |
| ROE | 8.3% | Middle | |
| Debt/equity | 0.13 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Bio-Techne. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$299.71M
Latest quarter · Q3 2026
Net income
$28.29M
Latest quarter · Q3 2026
Quarterly net margin
9.4%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $11.43B
- P/E
- 66.8
- EPS
- $1.09
- Volume
- 3.5M
- Daily trading
- €204.3M
- Dividend yield
- 0.44%
- Last ex-dividend on November 13, 2026
How Bio-Techne is changing
All resultsRevenue grew 5.5% a year on average over the last 5 years
Operating margin fell from 26.3% to 20.7%
Profits turn into cash: free cash flow equal to 179% of net income
Returns
Bio-Techne returns with dividends
$1,000 invested in Bio-Techne 5 years ago, on November 17, 2021, would be worth $603 today with dividends reinvested: −39.68% in total, −9.62% per year. On price alone it would be $589 (−41.06%).
| Period | Bio-Techne | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +0.39% | −3.17% | $1,004 |
| 6 months | +67.74% | +0.11% | $1,677 |
| Year to date | +23.75% | +8.34% | $1,237 |
| 1 year | +24.83% | +11.15% | $1,248 |
| 3 years | +21.05% | +64.30% | $1,210 |
| 5 years | −39.68% | +58.18% | $603 |
| 10 years | +192.23% | +239.10% | $2,922 |
Over the last 6 months it has done better than 95% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Bio-Techne: technical analysis
Bio-Techne is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 46.1% below its highest close since January 2, 1990 ($134.72, September 24, 2021).
- Trend
- Upward
- RSI (14 sessions)
- 48
- Between 30 and 70
- vs 200-session average
- +14.45%
Active signals
The price is moving in an unusually narrow range compared with the last year.
since August 25, 2026
Support and resistance
Price areas where Bio-Techne has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$72.63
- Support$72.34−0.40%15 touches, last on November 9, 2026
- Support$70.20−3.34%2 touches, last on July 8, 2026
- Support$58.73−19.14%2 touches, last on February 27, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.60
- Volatility (60 sessions, annualised)
- 1.9%
- Largest fall in the last year
- −39.34%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Bio-Techne: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Bio-Techne has been May: +5.02% on average, positive in 21 years out of 37. The weakest has been January: −1.56% on average, positive in 17 years out of 36. November, the current month, has been positive in 23 years out of 36 (+2.67% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −1.56% | −0.01% | 17 of 36 |
| February | +2.15% | +2.13% | 20 of 37 |
| March | +1.06% | +0.39% | 19 of 37 |
| April | +2.57% | +3.27% | 22 of 37 |
| May | +5.02% | +2.39% | 21 of 37 |
| June | +4.18% | +2.29% | 21 of 37 |
| July | +2.00% | +1.65% | 22 of 37 |
| August | +1.15% | +0.31% | 19 of 37 |
| September | +0.50% | 0.00% | 18 of 37 |
| October | +2.55% | +1.60% | 23 of 37 |
| November | +2.67% | +2.51% | 23 of 36 |
| December | +1.85% | +1.26% | 22 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Bio-Techne and its competitors
Based in Minneapolis, Minnesota, Bio-Techne has existed since its incorporation in 1976. Its portfolio centers on biological reagents such as cytokines, growth factors and antibodies, supplied to research laboratories, clinical diagnostics makers and developers of cell and gene therapies. It also offers diagnostic controls, calibrators and assays, tissue-based spatial analysis kits, and instruments and control products for hematology and blood chemistry. Known as Techne Corporation until November 2014, it serves customers across many countries.
- Headquarters
- Minneapolis, United States
- Employees
- 3,000
- Founded
- 1976
- Chief executive
- Kim Kelderman
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Bio-TechneTECH | $11.43B | 21.7% | 66.8 | +67.74% |
| Summit TherapeuticsSMMT | $11.32B | 0.0% | — | −36.75% |
| BioMarin PharmaceuticalBMRN | $11.09B | 16.3% | 146.8 | +12.93% |
| Madrigal PharmaceuticalsMDGL | $9.93B | -10.7% | — | −19.42% |
| Corcept TherapeuticsCORT | $9.36B | 0.8% | 190.2 | +24.30% |
| Halozyme TherapeuticsHALO | $14.67B | 56.8% | 38.3 | +42.98% |
Same industry or related industries, similar size. Compare Bio-Techne with its competitors · Full profile
